title: [A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of weekly or 3-week docetaxel in combination with capecitabine.
  
  
  METHODS
  83 Patients with at least one measurable lesion were randomized to receive the treatment arms: docetaxel 37.5 mg/m(2) on days 1 and 8, oral capecitabine 950 mg/m(2) twice daily on days 1-14 (Group A); docetaxel 75 mg/m(2) on days 1, oral capecitabine 950 mg/m(2) twice daily on days 1-14 (Group B). Each cycle was repeated every 3 weeks.
  
  
  RESULTS
  Eighty-three patients were enrolled, 78 eligible for tumor assessment. The overall clinical response rate of all groups was 61.4% (51/83). There was no progressive disease (PD) after two cycles. Efficacy outcomes were similar in the two groups. The response rate of group A and B were 61.8% (21/34) and 61.2% (30/49) respectively. There were no drug-related deaths observed. Neutropenia was the most common toxicity. In all, the frequency of Grade 3/4 neutropenia were 45.8% (38/83), but Grade 3/4 neutropenia of Group B 55.1% (27/49) was higher than Group A 32.4% (11/34), P = 0.04.
  
  
  CONCLUSIONS
  The study confirmed the superior activity of docetaxe-capecitabine combination therapy in anthracycline resistant MBC, and comparing with 3-week schedule, weekly docetaxel plus capecitabine has same high efficacy with a favourable safety profile.
authors.affiliation: Clinical Cancer Centre Hospital No. 307, Beijing 100071, China.
authors.forename: Shao-hua
authors.initials: SH
authors.lastname: Zhang
authors.forename: Ze-fei
authors.initials: ZF
authors.lastname: Jiang
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Xie
authors.forename: Yan
authors.initials: Y
authors.lastname: Wei
authors.forename: Jun
authors.initials: J
authors.lastname: Ren
authors.forename: Ji-wei
authors.initials: JW
authors.lastname: Liu
authors.forename: Wen-chao
authors.initials: WC
authors.lastname: Liu
authors.forename: Xia
authors.initials: X
authors.lastname: Li
authors.forename: Yu-xian
authors.initials: YX
authors.lastname: Bai
authors.forename: Shun-chang
authors.initials: SC
authors.lastname: Jiao
authors.forename: Qiang
authors.initials: Q
authors.lastname: Sun
authors.forename: Duan-qi
authors.initials: DQ
authors.lastname: Liu
authors.forename: Ju-xiang
authors.initials: JX
authors.lastname: Xiao
authors.forename: Hua-qing
authors.initials: HQ
authors.lastname: Wang
authors.forename: Li-li
authors.initials: LL
authors.lastname: Tang
authors.forename: Ying
authors.initials: Y
authors.lastname: Cheng
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Yong-sheng
authors.initials: YS
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010865:Pilot Projects; D043823:Taxoids / Q000008:administration & dosage; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D005472:Fluorouracil